Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Ocrelizumab is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B lymphocytes that express the CD20 antigen. B lymphocytes are known to promote the pathogenesis of MS by activating pro-inflammatory T cells and secreting pro-inflammatory cytokines. Ocrelizumab promotes cytotoxicity of antibody-dependent cells and complement-mediated cell lysis by binding to CD20-expressing B lymphocytes. Ocrelizumab may induce antibody-dependent cytotoxicity, involving macrophages, natural killer cells, and cytotoxic T cells that work together to cause cell death.
Multiple Sclerosis, Primary Progressive
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.